Galderma agrees to buy ZO Skin Health for around $1.5 billion, sources say

By Reuters News

By Abigail Summerville

NEW YORK, Oct 13 (Reuters) - Swiss skincare conglomerate Galderma GALD.S has agreed to buy medical-grade skincare company ZO Skin Health for around $1.5 billion, according to two people familiar with the matter.

A deal could be announced in the coming days, the people said.

ZO and Galderma, which were contacted outside regular business hours, did not immediately respond to requests for comment.

ZO's owner, investment firm Blackstone BX.N, was exploring a sale of the company with investment banks Citigroup C.N and Raymond James RJF.N, Reuters reported last month. Blackstone declined to comment on Tuesday.

The move by dermatology company Galderma, in which beauty giant L'Oréal OREP.PA owns a 20% stake, will expand its presence in the US market. In August, the company opened a US and Latin America headquarters in Miami.

Established in 1981, Galderma also owns skincare brands Cetaphil and Alastin Skincare, Differin Epiduo acne gel, injectable neurotoxin Dysport, and dermal filler brand Restylane.

Many strategic buyers ​are prioritizing clinically backed, physician-distributed skincare brands like ZO because of their efficacy ⁠and ​steadier demand versus ​over-the-counter products.

Dermatologist ⁠Zein Obagi founded ZO in 2007. ZO sells skincare products including cleansers, serums, exfoliators and toners ​that are ​distributed by ⁠physicians and skincare professionals.

Blackstone acquired ZO through its tactical opportunities fund in 2020.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.